Portrazza FDA Approval History
FDA Approved: Yes (First approved November 24, 2015)
Brand name: Portrazza
Generic name: necitumumab
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Non-Small Cell Lung Cancer
Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer.
Development timeline for Portrazza
| Date | Article |
|---|---|
| Nov 24, 2015 | Approval FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
